Rezolute, Inc. hosted a virtual key opinion leader (KOL) event focused on the therapeutic landscape of Diabetic Macular Edema, scientific rationale for an oral plasma kallikrein inhibitor (PKI) to target the disease, and the potential of RZ402, the company's oral PKI, to change the standard of care as a safe, effective, and less invasive treatment option. In December 2022, Rezolute announced the initiation of a Phase 2 study of RZ402 in patients with DME. The Phase 2 study is a multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are nave to or have received limited anti-VEGF injections.

Top line results for the Phase 2 study are anticipated in the first quarter of 2024.